Pathophysiology of reversible cerebral vasoconstriction syndrome

Shih-Pin Chen¹,²,³,⁴*† and Shuu-Jiun Wang¹,⁴*†

Abstract

Reversible cerebral vasoconstriction syndrome (RCVS) is a complex neurovascular disorder being recognized during the past two decades. It is characterized by multiple abrupt severe headaches and widespread cerebral vasoconstrictions, with potential complications such as ischemic stroke, convexity subarachnoid hemorrhage, intracerebral hemorrhage and posterior reversible encephalopathy syndrome. The clinical features, imaging findings, and dynamic disease course have been delineated. However, the pathophysiology of RCVS remains elusive. Recent studies have had substantial progress in elucidating its pathogenesis. It is now believed that dysfunction of cerebral vascular tone and impairment of blood–brain barrier may play key roles in the pathophysiology of RCVS, which explains some of the clinical and radiological manifestations of RCVS. Some other potentially important elements include genetic predisposition, sympathetic overactivity, endothelial dysfunction, and oxidative stress, although the detailed molecular mechanisms are yet to be identified. In this review, we will summarize what have been revealed in the literature and elaborate how these factors could contribute to the pathophysiology of RCVS.

Keywords: Reversible cerebral vasoconstriction syndrome, Thunderclap headache, Blood–brain barrier, Neurovascular unit

Introduction

Reversible cerebral vasoconstriction syndrome (RCVS) is a complex neurovascular syndrome characterized by multiple abrupt, severe headaches, namely thunderclap headaches, and diffuse segmental constriction of cerebral arteries [1, 2]. The term RCVS was proposed as a unifying nomenclature in 2007 [3] for varieties of historical labeling such as Call–Fleming syndrome [4], thunderclap headache with reversible vasospasm [5, 6], benign angiopathy of the central nervous system (CNS) [7], postpartum angiopathy [8, 9], migrainous vasospasm or migraine angiitis [10], or drug-induced cerebral arteritis or angiopathy [11, 12], depending on whether patients present to specialists in stroke, headache, rheumatology, or obstetrics, etc. Accordingly, RCVS has been seen by physicians across disciplines but only until the past two decades has it been recognized as a distinct clinic-radiological syndrome. Large case series of RCVS have been reported in Asia, Europe and America [2, 13–20]. Yet, the exact epidemiology of RCVS remains unclear. Based on an analysis of the United States Nationwide Inpatient Sample database (2016–2017), > 1000 patients with RCVS are hospitalized each year in the entire population of the United States [21]. The survey of hospital-based headache clinics demonstrated that RCVS accounts for nearly 2% of the headache patients in Taiwan [2, 13, 14]. In patients with young stroke (< 45 years), RCVS constitutes up to 13% of the cases in a multicenter Italian study [18]. Hence, RCVS may not be as rare as we thought before. However, whether there is a geographic discrepancy in the prevalence or incidence of RCVS is unclear. Research on this distinct syndrome has accumulated rapidly in an exponential way after the term RCVS being
proposed. The clinical features of RCVS have been well delineated; however, the pathogenesis of RCVS remains elusive. Nevertheless, there is substantial breakthrough in understanding the pathogenesis of RCVS during the past few years. In this review, we will briefly outline the clinical features, significance and impact of RCVS and elaborate in detail what has been known on its pathogenic mechanism.

Clinical features, significance and impact

RCVS can be either idiopathic [2, 13] or secondary to various factors [15]. An expanding list of possible etiologies of RCVS has been identified [2, 3, 15, 17, 22]. Comprehensive reviews can be found elsewhere [1, 23, 24]. Overall, vasoactive substances and post-partum state are the most common secondary causes of RCVS. In previously reported large series, RCVS is predominately idiopathic in Asian populations while the opposite is observed in Europeans or Americans [2, 13–20]. Patients with RCVS are predominantly female with age around 40–55, while male patients are 10 years younger than the female patients [2, 15, 17]. The clinical hallmark of RCVS, i.e., recurrent thunderclap headaches, are usually evoked by precipitants that are common in daily lives such as defecation, exertion, sexual activity, urination, or cough, bathing or sudden emotional outbursts. Patients often avoid encountering these common daily activities to prevent themselves from the terrifying headaches. These headaches may last for hours long per attack and recur for multiple times within 2–3 weeks of disease onset [2, 15, 17, 25]. Abrupt blood pressure surges accompanying headache attacks can be seen in more than one-third of patients [2, 14, 15]. The vasoconstrictions, which are usually segmental and involving multiple intracranial arteries, may take 3 months to recover (Fig. 1) [13, 14]. The vasoconstriction may sometimes alternate with vasodilatation, involving distal branches of cerebral arteries or arterioles, and propagate centripetally during the disease course [14, 26, 27].

Not only the severe headache that profoundly interfering quality of life, patients with RCVS may also suffer from potentially devastating complications or comorbid conditions. Nearly one-third of patients with RCVS may experience seizure [2, 3, 15, 17], transient neurological deficits [2, 3, 15, 17], ischemic stroke [13–15, 17, 19], convexity subarachnoid hemorrhage (cSAH) and/or intracerebral hemorrhage [28, 29], or posterior reversible encephalopathy syndrome (PRES) [13–15, 17, 19] during the disease course (Fig. 2). Cervical artery dissection is also a common comorbid condition of RCVS [30]. The severity of vasoconstriction is associated with risks of PRES or ischemic stroke [13, 29] whereas female gender, migraine, history of hypertension, and use of cocaine are risk factors for hemorrhagic complications [16, 29, 31]. Patients may be left with permanent neurological deficits [14, 16, 17, 32]. Death has also been reported in a few cases [17, 33, 34]. Calcium channel blockers, particular nimodipine, may be helpful for aborting headaches [2, 14, 35]. Nearly half of the patients with RCVS may develop post-RCVS headache that could linger for more than 1 year after remission of vasoconstriction [36]. Moreover, 5–10% of the cases may recur during long-term follow-up [37, 38]. Hence, even when the disease has remitted, the long-term risk of RCVS recurrence should not be neglected.

Pathophysiology

The exact pathophysiology of RCVS remains enigmatic. Because the etiologies of RCVS are heterogeneous, the underlying mechanisms are likely multi-factorial.
Observations from clinical features or secondary RCVS have provided important clues to formulate hypotheses. For example, biological effects exerted by the exposed substances [39] or humoral factors associated with puerperium [40, 41] may also contribute to the pathogenesis in idiopathic cases. However, in-depth investigations to validate these hypotheses are relatively scarce. One major limitation is that it is difficult to obtain histopathological samples from the affected vessels or brain. Moreover, in a retrospective study that had 17% of the patients received open brain biopsy or full autopsy [17], extensive histological studies demonstrated no evidence of arterial inflammation or infection. One case report which detailed both histological and electron-microscopical examinations showed that major cerebral arteries were normal except for a patch of subendothelial thickening in the posterior cerebral artery [42]. That is, even with histopathological specimens, no specific pathology has been identified in RCVS. Nevertheless, recent studies have identified some plausible elements that may regulate or reflect the pathogenic alterations of RCVS. Herein we summarized evidence supporting these elements and elaborate how these factors could interact with each other and contribute to the pathogenesis of RCVS.

**Dysregulation of cerebral vascular tone**

Based on the radiological features, dysregulation of cerebral vascular tone has been considered the central element in the pathogenesis of RCVS [1, 23, 24]. An abrupt, unpredictable alteration of central vascular tone associated with excessive sympathetic discharge may explain the cerebral vasoconstriction and, the less mentioned, vasodilatation. As pial cerebral arteries are densely innervated by the superior cervical ganglion (and also sparsely by the sphenopalatine, otic or trigeminal ganglion) [43], the release of norepinephrine or neuropeptide Y from the sympathetic nerve endings may cause vasoconstrictions. However, it is uncertain whether the vasoconstriction is the direct consequence of the suddenly increased sympathetic drive caused by triggers or secondary etiologies, or the passive autoregulatory response of the perivascular sympathetic innervation to protect the brain against the abrupt blood pressure surge accompanying the severe headache. Clinical observations support the possibility of both scenarios.

In contrast to pial cerebral arteries, cerebral microcirculation receives intrinsic innervations from the locus coeruleus, raphe nucleus, basal forebrain, or local cortical interneurons [43]. These perivascular nerves intricately regulate the cerebral microvascular tone and autoregulation via populations of receptors within the different cellular compartments of the neurovascular unit. The vascular response of pial cerebral arteries or parenchymal microvasculature to neurotransmitters may differ depending on the distribution of the postjunctional receptors. For instance, norepinephrine causes contraction in the middle cerebral arteries through activation of the α1-adrenoreceptors [44, 45] but elicits dilation of parenchymal arterioles due to the predominant distribution of β-adrenoreceptors [46]. The vasomotor responses of the cerebral microvasculature may be altered preceding the grossly perceivable caliber change of large cerebral arteries, based on the observations of centripetal propagation of vasoconstriction [26, 27] and the different time course of hemorrhagic and ischemic complications [15]. The hemorrhagic complications or brain edema due to the dysfunction of blood–brain barrier (BBB) or neurovascular unit tend to occur during the first 2 weeks of the disease while ischemic complications tend to occur later, either caused by the hypoperfusion due to severe
vessels, the pathogenesis of major arterial segments or the transformation of vasogenic edema into cytotoxic edema in patients with PRES [1, 6, 14, 23]. In fact, autoregulation failure has been considered important in the pathogenesis of PRES [47, 48], an overlapping syndrome or complication of RCVS.

Direct evidence supporting dysregulation of cerebral vascular tone derived from studies investigating the cerebrovascular reactivity in patients with RCVS [49, 50]. In a retrospective case series, the Breath Holding Index, which measures cerebral endothelium-dependent vasodilation in response to hypercapnia, was severely impaired in patients with RCVS during the acute stage of disease [49]. Similar findings were also observed in another case-control study, which demonstrated not only impaired cerebrovascular reactivity during the acute stage but also recovery of the impaired cerebrovascular reactivity in the remission stage in 70% of the cases who received follow-up [50]. Autonomic dysregulation [51], oxidative stress [52, 53], impaired endothelial repair capacity [54], and disruption of the BBB [55, 56] might contribute to the altered cerebrovascular reactivity, which are detailed below. Moreover, a recent study identified a panel of microRNAs (miR-130a-3p, miR-130b-3p, let-7a-5p, let-7b-5p and let-7f-5p) that can be used to differentiate patients with RCVS (in acute stage) from controls with nearly 90% accuracy [57]. The common targets of these circulating microRNAs include genes responsible for cerebral vascular tone, such as EDN1 (endothelin-1) or genes involved in the transforming growth factor-beta (TGF-β) signaling pathway [57]. These findings may serve as primers for future studies to investigate potential molecular mechanisms.

**Sympathetic overactivity**

Aberrant sympathetic response of cerebral vasculature has been long proposed important in the pathogenesis of RCVS [58], which can be partly supported by the fact that RCVS can occur in some patients with pheochromocytoma [59–61], after the use of sympathomimetic vasoactive substances [12, 14, 15, 17, 62], or acute hypertensive crises [63]. Besides, clinical features such as abrupt blood pressure surge [2, 15] and/or the Valsalva maneuver-like triggers with elevated sympathetic tone [2, 15] also implicate the role of sympathetic overactivity in the pathogenesis.

In a 24-h heart rate variability study, patients with RCVS were found to have heightened sympathetic activity and attenuated parasympathetic modulations during the acute stage [51]. This autonomic dysregulation only partially recovered at the remission stage, suggesting that patients with RCVS might have some predisposition of sympatho-vagal imbalance that makes them vulnerable to external triggers. Alternative explanation is that, once afflicted by the disease, the autonomic dysfunction could not recover soon even after resolution of vasoconstrictions. An indirect support for the sympatho-vagal imbalance predisposition is the higher occurrence of RCVS in cold weather [64]. The sympathetic nervous system might be more excitable in cold weather and thus aggravate a pre-existing sympatho-vagal imbalance and thus induce cerebral vasoconstriction. It has been shown that cerebrovascular resistance increases during cold face stimulation [65] and sympathetic stimulation during cold pressor testing may produce constriction of large cerebral arteries to protect the brain from arterial pressure elevations [66], which might be related mechanistically to cerebral vasoconstriction in RCVS. Additionally, a genetic polymorphism study showed that the brain-derived neurotropic factor (BDNF) Val66Met functional polymorphism is linked to vasoconstriction in patients with RCVS [67]. Preclinical study identified that BDNF could cause perivascular inflammation and vasoconstriction under circumstances of sympathetic overactivity [68]. BDNF could also upregulate neuropeptide Y, a vasoconstrictor secreted by sympathetic nerve endings [69]. Nevertheless, these links are tangential and require further studies to validate.

**Endothelial dysfunction**

The cerebrovascular endothelium exerts a profound influence on cerebral vascular tone [70]. It is plausible that the dysregulated cerebral vascular tone in RCVS may in part attributed to endothelium-dependent mechanism. In fact, the impaired endothelium-dependent vasodilation to hypercapnia in patients with RCVS [49, 50] supports this notion. In addition, one study identified that patients with RCVS have reduced circulating CD34+KDR+ endothelial progenitor cells (EPCs) in comparison with controls, especially in those with more severe vasoconstrictions [54]. The number of CD34+KDR+ EPCs was negatively correlated with the severity of vasoconstrictions. Because cells expressing CD34 (an adhesion molecule expressed on hematopoietic stem cells) and KDR (a tyrosine kinase receptor that upregulate neuropeptide Y, a vasoconstrictor secreted by sympathetic nerve endings) might be the main constituent of the circulating EPCs responsible for re-endothelialization [71], it is plausible that patients with RCVS may have reduce impaired endothelium repair capacity during the acute stage of the disease, either due to lower baseline level or an accelerated consumption and/or senescence of circulating EPCs under the circumstance of sympathetic overactivity and excessive oxidative stress.

Studies from overlapping syndromes or spectral disorders of RCVS also support the existence of endothelial
dysfunction at least in selected cases. PRES, a well-recognized cerebral endotheliopathy [72], can be found in a substantial proportion of patients with RCVS [6, 13, 14, 16, 17], and with similar characteristics of RCVS including dysregulated vascular tone, acute severe headaches, blood pressure surge, and secondary etiologies such as immunosuppressive or cytotoxic agents [24, 47, 48]. Post-partum angiopathy, one of the secondary RCVS, exhibits overlapping clinical, laboratory and radiographical features with the obstetric emergencies eclampsia and preeclampsia [22, 73, 74]. Previous studies demonstrated that placental growth factor (PIGF), soluble PIGF receptor (sFlt-1) [40, 41], and soluble TGF-β1 receptor (soluble endoglin) [75] correlate with the presence of eclampsia and the ratio of sFlt-1 to PIGF could also be used to predict the occurrence of pre-eclampsia [41]. The balance of these antiangiogenic and proangiogenic factors could also play a role in the pathogenesis of post-partum angiopathy [42]. Whether patients who are not pregnant or in the puerperium could exhibit similar mechanisms associated with the imbalance of certain humoral factors regulating endothelial function requires further studies.

It has been questioned whether the endothelial dysfunction is restricted to the brain or could be systemic. In a study in which 18 patients with RCVS received transthoracic echocardiography during the acute stage, three (17%) had transient wall motion abnormalities [76]. Another two case reports also demonstrated transient myocardial ischemia [77] or coronary vasospasm [78] responsive to calcium channel blockers. Because of the rarity of these cases, whether RCVS has extracranial vascular involvement remains inconclusive.

Blood–brain barrier disruption

BBB is the main anatomical barrier that separates blood from the microenvironment of brain, regulating the exchange of ions, nutrients, and energy metabolites [85, 86]. The core element of the BBB, the endothelial cells, limits the paracellular and transcellular transport by continuous inter-endothelial tight junctions and the extremely low transcytotic activity. The endothelial cells, pericytes and smooth muscle cells of the vessel, glia cells, and neurons collectively form the neurovascular unit which is responsible for the highly coordinated neurovascular coupling. As vascular tone is delicately regulated by neurovascular unit, it is rational to speculate that a dysfunctional BBB may participate in the pathogenesis of RCVS. When the cerebral autoregulation is profoundly overwhelmed, the integrity of BBB might be breached, and ischemic or hemorrhagic complication might ensue [23, 87]. In fact, reactive oxygen species have been found to contribute to BBB disruption by oxidative damage to cellular molecules, activation of matrix metalloproteinases, reorganization of cytoskeleton, modulation of tight junction proteins, and upregulation of inflammatory mediators [88]. A recent study on the white matter hyperintensity lesions (WMHs) in RCVS also implicates that transmission of excessive central pulsatile flow to cerebral microcirculation upon episodic blood pressure surge may lead to increased microvascular damage, increased vascular permeability, and impaired solute clearance, contributing to WMH formation [89]. With severe breakdown of BBB, hemorrhagic complications or brain edema may ensue.

Beyond hypothesis-driven approach, a study combined 1H-nuclear magnetic resonance and LC-MS/MS to discover potential urine metabolic signatures in patients with RCVS [53]. Six metabolites, hippurate, citrate, 1,3,7-trimethyluric acid, ascorbic acid, D-glucurono-6,3-lactone, and D-threo-isocitric acid, were identified as the most discriminative metabolites for RCVS. Of them, hippurate, citrate, ascorbic acid, and D-glucurono-6,3-lactone were significantly lower, and 1,3,7-trimethyluric acid and D-threo-isocitric acid were higher in RCVS patients. These metabolites are related to two metabolic networks including free radical scavenging and vitamin/mineral metabolism, further validating the potential role of oxidative stress in the pathogenesis of RCVS. Moreover, the hub molecules within the metabolic networks are also associated with endothelial dysfunction or sympathetic overactivity, supporting the complex interaction of these elements in the disease pathogenesis [53].
BBB breakdown in RCVS [55]. This study revealed that nearly 70% of patients with definite RCVS and one-fourth of patients with probable RCVS had BBB breakdown. In addition, BBB breakdown was found to be an independent risk factor for neurological complications, in particular convexity SAH and PRES [55]. A subsequent international collaborative study demonstrates that the BBB breakdown was worse during the first 1–2 weeks and with a temporal course similar to but earlier than that of vasoconstrictions which peaked at the 3rd week [56]. This finding may provide a pathophysiologic background of the temporal course of neurological complications of RCVS, i.e., the hemorrhagic complications or PRES tend to occur early in the disease course whereas ischemic stroke occurs later. In addition, blood pressure surge was found to be a risk factor of BBB breakdown, supporting the speculation of the injurious effect of excessive central pulsatile flow on the brain [89].

Because the presence of macroscopic BBB disruption in patients with RCVS using CE-T2-FLAIR imaging (Fig. 3) could only be identified in half of the patients with RCVS [56, 90], a recent study interrogated whether the brain permeability in patients without discernible macroscopic BBB disruption is altered using a technique called dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). The microscopic BBB permeability in the whole brain and WMHs was determined using an index \( K_{\text{trans}} \) [91]. It was found that patients with RCVS presented increased microscopic permeability of the whole brain and WMHs during acute stage, even without discernible macroscopic BBB disruption on CE-FLAIR. In addition, a dynamic change in BBB permeability was noted, which was correlated with impaired cerebral microvascular compliance assessed with hemodynamic studies and may thus contribute to WMH formation [91].

A recent study identified a panel of circulating microRNAs that may serve as potential disease signature of RCVS [57]. These microRNAs are functionally associated with acute headache, vasomotor control or BBB regulation. Remarkably, miR-130a-3p was associated with imaging-proven BBB disruption in patients with RCVS and its overexpression led to reduced transendothelial electrical resistance (i.e., increased permeability) in vitro human BBB model [57]. Consistent with this finding, two previous studies have disclosed that miR-130a could increase BBB permeability under ischemic [92] or hemorrhagic conditions [93]. Interestingly, the abundance of miR-130a and miR-130b was associated with blood pressure surge during the acute stage of RCVS. This might be compatible with the mechanosensitive nature of the miR-130/301 family [94], i.e., the expression of miR-130 was upregulated in response to the shearing stress induced by abrupt hemodynamic change upon blood pressure surge. Future studies are needed to explore the mechanism how the upregulated miR-130a interferes BBB permeability.

### Altered trigeminovascular nociception

The cause of thunderclap headache may be the most enigmatic part in the pathogenesis of RCVS. Because the headaches usually recur for multiple times during the first 2 weeks after disease onset while the constriction of major cerebral arterial segments peaked at the 3rd week [13, 14, 56], vasoconstriction of the large or medium-sized cerebral arteries is unlikely to be the cause of the headache. Previously, intracranial pain-sensitive structures are believed to be the dura mater and its feeding vessels. However, a recent study based on the mapping in awake craniotomies in patients suggests that the pia and small cerebral vessels are also pain-sensitive [95]. Based on this updated neuroanatomical knowledge as well as the disease temporal course, the involvement of distal arterioles is more likely the primary trigger activating the trigeminovascular nociceptive pathway in RCVS [95]. Physiologically, the trigeminovascular pathway, which provides the unique sensory innervation to brain vessel, acts as a “protective” system that restores vessel tone after vasocontractile stimuli, probably via the potent
vasodilatory neuropeptide calcitonin gene-related peptide (CGRP) released from trigeminal nociceptors [43]. In RCVS, this reflex could be exaggerated but yet to be proved. Increased BBB permeability during the early stage of disease course could also be an important contributor to the headache by activating the trigeminal nociceptors via the leaked intravascular components; however, in-depth studies are still needed.

A recent study found that circulating microRNAs including let-7a-5p, let-7b-5p and let-7f-5p were upregulated both in acute stage of RCVS and ictal stage of migraine and returned to normal in the remission stage of RCVS or interictal stage of migraine [57]. Hence, these microRNAs might be associated with acute pain or certain mechanism shared by RCVS and migraine, such as CGRP-dependent trigeminovascular reflex. Previous studies showed that let-7b is highly expressed in and can be released from dorsal root ganglion (DRG) [96]. Inhibition of let-7b attenuated formalin-induced TRPA1 currents in the DRG neurons and spontaneous pain [96], while TRPA1 activation could trigger CGRP release from the trigeminal ganglion and mediate trigeminovascular reflex [97]. In addition, injecting anti-let-7 into the brain reduces opioid antinociceptive tolerance in mice [98]. Whether these mechanisms could explain the pain in RCVS require further investigations.

Genetic predisposition

Because of the potential of recurrence [37, 38] and the partially-persistent dysfunctional traits during the remission stage [51], it is reasonable to speculate that patients with RCVS might have some genetic predisposition that makes them vulnerable to the disease. However, no obvious inheritance pattern has been identified. As there are multiple environmental factors that could lead to RCVS, it is likely RCVS is a complex disease modulated by multiple genes with small or moderate effect sizes. Yet, no definite susceptible gene for RCVS has been identified. Only two genetic association studies have been conducted in patients with RCVS. One study found that patients carrying the Val allele of BDNF Val66Met polymorphism were more likely to have more severe vasoconstrictions than Met homozygotes [67]; however, the genotype frequencies in RCVS patients were not different from that in normal controls. Another study investigated Ring Finger Protein 213 (RNF213), a susceptibility gene of moyamoya disease and intracranial artery stenosis and dissection, in patients with RCVS found no association between the gene and disease [99].

In a case report, a 9-year-old boy with Loeys–Dietz Syndrome caused by a heterozygous TGFBR2 (encoding for type II TGF-β receptor) mutation was diagnosed with RCVS with PRES [100], suggesting the potential role of TGF-β signaling pathway in the pathogenesis of RCVS. Interestingly, TGF-β signaling pathway is also the most significant pathway identified by pathway enrichment analysis for the predicted target genes of the RCVS-selective circulating microRNAs [57]. TGF-β has been known to induce the vascular endothelial expression of endothelin-1, a predicted common target of all five RCVS-selective microRNAs. In vitro study, the expression of EDN1 expression as well as predicted genes within the TGF-β signaling, including the TGFBR2, was inhibited by the patients’ cerebrospinal fluid, validating in silico findings. Although it is likely most RCVS patients would not have monogenic mutations involving TGFBR2 or EDN1 genes, it would be interestingly to investigate potential functional polymorphisms of these genes in these patients. Considering the complex nature of the disease, non-hypothesis driven genome-wide based approach might be even helpful to identify possible susceptible genes although this would require a large number of patients via international collaborations.

Sex hormones

Patients with RCVS are predominantly female of middle age, particularly around perimenopause. Postpartum angiopathy also occurs at the stage when hormones fluctuate dramatically. As cerebral vascular tone and BBB permeability are heavily influenced by the effects of estrogen and progesterone mediated signaling pathways [101], it has long been proposed that sex hormones play important roles in the pathogenesis of RCVS. However, direct evidence is lacking. In a few case reports, the occurrence of RCVS was associated with an acute withdrawal or administration of hormones, such as bilateral salpingo-oophorectomy [102], hormonal ovarian stimulation for intrauterine insemination [103], oral contraceptive pills [104], or levonorgestrel-releasing intrauterine system [105]. However, it is difficult to establish causality based on selected case reports. In a large retrospective study that investigated the potential hormonal influences on RCVS, no significant differences between pre- and post-menopausal women, or those with and without hysterectomy were observed [106]. Hence, it remains inconclusive whether hormonal imbalance could trigger or modify the disease course of RCVS.

Inflammation

Previously, RCVS was considered a benign angiopathy of the CNS, which should be differentiated from primary angiitis of the CNS (PACNS) [107–109]. Limited histopathological data also do not support the presence of arterial wall inflammation in patients with RCVS [32, 109, 110]. However, marked vascular wall enhancement has been noted in a patient with cocaine vasculitis [111],
and cocaine has been considered to be an important etiology of RCVS [1, 17, 109]. A study used high-resolution vascular wall imaging demonstrated enhancement of the diseased vessels in almost half patients with idiopathic RCVS, suggesting that there might be subclinical perivascular inflammation in some patients [112]. Furthermore, a study demonstrated five patients with hemorrhagic PACNS were exclusively associated with sympathomimetic drug exposure and presented as thunderclap headache and self-limited clinical course, which substantially overlapped with the clinical presentations of RCVS [113]. Hence, it is possible that RCVS shared certain pathogenic mechanisms of PACNS, and inflammation could contribute to the vasoconstrictions at least in certain patients. Some other case reports also suggested a potential link between inflammation and RCVS. For example, some patients with systemic lupus erythematosus have been reported to have RCVS [114–116]. Coronavirus disease 2019 (COVID-19) and the multisystem inflammatory syndrome in children (MIS-C) following COVID-19, both with remarkable endothelial inflammation, were also recently linked to RCVS [117–122]. Further studies are needed to elucidate the potential causality and mechanisms between these inflammatory disorders and RCVS.
Proposed model of the pathophysiology of RCVS

Based on the potential elements elaborated above, we propose a model for the pathophysiology of RCVS (Fig. 4) and summarize the main mechanism and strength of evidence for each proposed element of pathophysiology (Table 1). Patients with certain predisposition (possibly related to some susceptible genes) may be more vulnerable to triggers with heightened sympathetic drive, secondary causes (such as the use of vasoactive substances or postpartum), systemic inflammation, or adverse environments such as cold weather. When the central or systemic sympathetic system is ignited and overacted, a sudden release of vasoconstrictors such as catecholamines, neuropeptide Y or endothelin-1 may cause an abrupt dysregulation of cerebral vascular tone. The impaired autoregulation may initially manifest as dilations of distal arterioles, partly due to an exaggerated trigeminovascular reflex. The dilatation of distal arterioles, capillaries or meningeal collaterals may abruptly stretch the perivascular nociceptive nerve fibers to cause thunderclap headaches. In addition, excessive central pulsatile flow related to blood pressure surge may cause the dysfunction of neurovascular unit and increased BBB permeability, which may also contribute to impaired cerebral vascular tone and headache. Furthermore, to counteract the excessive pulsatile flow and distal arteriole dilation, the large or medium-size cerebral arteries constrict subsequently, manifesting as centripetal propagation of vasoconstrictions during the disease course.

With persistently heightened sympathetic drive, endothelial dysfunction and excessive production of oxidative stress ensue, leading to a vicious cycle that further perpetuates the dysregulation of cerebral vascular tone. The endogenous endothelial repairing capacity may thus stretch the perivascular nociceptive nerve fibers to cause thunderclap headaches. The vasoactive metabolites produced in response to free radicals such as 8-iso-PGF2α or the intravascular plasma components leaked to the paravascular CSF space due to BBB disruption may further

| Key elements                        | Main mechanism                                                                 | Strength of evidence | Possible treatment strategiesa |
|-------------------------------------|-------------------------------------------------------------------------------|----------------------|-------------------------------|
| Dysregulation of cerebral vascular tone | • Suddenly increased sympathetic drive  
  • Passive autoregulatory response against blood pressure surge  
  • Consequences of endothelial dysfunction, oxidative stress, and BBB disruption  
  • Dysregulated circulating miRNAs associated with vasomotor regulation | +++                  | • Early identification and avoidance of triggers or secondary causes with heightened sympathetic drive  
  • Cerebrovascular-selective calcium channel blockers? |
| Sympathetic overactivity             | • Predisposing sympatho-vagal imbalance  
  • Triggers or secondary causes associated with heightened sympathetic drive | ++                   | • Early identification and avoidance of triggers or secondary causes |
| Endothelial dysfunction              | • Impaired endothelial repairing capacity (i.e., reduced endothelial progenitor cells)  
  • Systemic endotheliopathy caused by secondary causes | +++                  | • Avoidance or early removal of secondary causes |
| Excessive oxidative stress           | • Increased reactive oxygen species and lipid peroxidation upon increased shearing stress and endothelial dysfunction | ++                   | • Antioxidants? |
| Blood–brain barrier disruption       | • Excessive blood pressure surge and pulsatile flow exceeding autoregulatory capacity  
  • Oxidative stress  
  • Circulating microRNAs (miR-130a) | +++                  | • Avoid blood pressure surge  
  • Antioxidants? |
| Altered trigeminovascular nociception | • Sudden stretch of perivascular trigeminal nociceptors (by dilatation of distal arteriole or meningeal artery)  
  • Increased BBB permeability  
  • Altered circulating microRNAs | ?                    | • The cerebrovascular-selective calcium channel blocker nimodipine  
  • CGRP-targeting therapy? (with risk of vasoconstriction) |
| Genetic predisposition               | • Genetic contribution to disease vulnerability | +                    | • Gene-based mechanism targeting therapy? |
| Sex hormones                         | • Hormonal modulation of cerebral vascular tone | +                    | • Avoid abrupt hormonal fluctuation in vulnerable subjects? |
| Inflammation                         | • Systemic or perivascular inflammation causing endothelial dysfunction | +                    | • Anti-inflammatory therapy? (Of note, steroid may be associated with poor prognosis) |

Table 1 Summary of potential pathophysiology of RCVS

Strength of evidence: +++: supported by multiple studies from different research groups; ++: supported by at least one study from single research group; +: based only on clinical observations; ?: based only on hypothesis

a Treatment without direct supporting evidence is ended with a question mark
aggravate vasoconstriction. Inflammation of vascular wall may develop in selected cases along with prolonged vasoconstrictions. In addition, in response to the shearing stress of excessive blood flow and deranged vascular tone, the expression of some microRNAs including miR-130a-3p, miR-130b-3p, let-7a-5p, let-7b-5p and let-7f-5p is upregulated. While countering the effect of vasoconstrictive genes such as EDN1 or those within the TGF-β signaling pathway, these microRNAs may also differentially participate in the genesis of the acute headache or BBB disruption.

The breakdown of BBB and excessive central pulsatile flow may lead to WMHs as well as the early complications such as PRES, convexity SAH or intracerebral hemorrhage. In contrast, vasoconstrictions of major arteries may lead to hypoperfusion, which might aggravate WMHs or when profound, lead to ischemic complications or aggravate the vasogenic edema of PRES lesions to cytotoxic edema.

Of note, because of the limitation of available studies, only some of the aforementioned mechanisms such as sympathetic overactivity or endothelial dysfunction can be applicable to both idiopathic RCVS and RCVS with secondary causes. As most of the mechanisms with better supporting evidence were derived from studies involving predominantly idiopathic cases, whether these mechanisms could be extrapolated to RCVS with secondary causes require further studies.

Conclusion

RCVS is a complex neurovascular disorder with dramatic clinical presentation, dynamic disease course, and potentially devastating complications. Recent research has provided substantial progress in understanding its pathophysiology, particularly on the dysregulation of cerebral vascular tone and disruption of BBB, although vast areas of unknowns remain to be explored. By unraveling the complex neurobiology of RCVS, we may be able to subclassify the syndrome with pathophysiology-specific perspectives and formulate potential disease-targeting management in the future.

Acknowledgements

Not applicable.

Author contributions

SPC and SJW are responsible for the conception and writing of the manuscript. Both authors read and approved the final manuscript.

Funding

This work was supported by the Brain Research Center, National Yang Ming Chiao Tung University from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan (to SJW & SPC); the Ministry of Science and Technology, Taiwan (MOST-107-2314-B-010-021, 108-2314-B-010-022-MY3 & 110-2326-B-A49A-501-MY3 (to SPC) and MOST 108-2321-B-010-014-MY2, 108-2321-B-010-001-, 108-2314-B-010-023-MY3, 110-2321-B-010-005- & 111-2321-B-A49-004- (to SJW), Ministry of Health and Welfare, Taiwan [MOHW107-TDU-B-211-123001 and MOHW 108-TDU-B-811-133001 (to SJW), and Taipei Veterans General Hospital, Taiwan [VGH-106-D9-001-MY2-2 (to SJW) & V111C-158, V109D52-001-MY3-3, VGHUST110-G1-3-1 (to SPC)The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials

All data are available in the manuscript and figures.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors have declared no competing interests.

Author details

1 Department of Neurology, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan. 2 Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. 3 Division of Translational Research, Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan. 4 Brain Research Center & School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.

Received: 28 July 2022 Accepted: 14 September 2022

Published online: 21 September 2022

References

1. Ducros A. Reversible cerebral vasoconstriction syndrome. Lancet Neurol. 2012;11(10):906–17.
2. Chen SP, Fuh JL, Lirng JF, Wang SJ. Recurrent primary thunderclap headache and benign CNS angiopathy: spectra of the same disorder? Neurology. 2006;67(12):1159–9.
3. Calabrese LH, Dodick DW, Schwedt TJ, Singhal AB. Narrative review: reversible cerebral vasoconstriction syndromes. Ann Intern Med. 2007;146(1):34–44.
4. Call GK, Fleming MC, Sealton S, Levine H, Kistler JP, Fisher CM. Reversible cerebral segmental vasoconstriction. Stroke. 1988;19(9):1159–70.
5. Dodick DW, Brown RD Jr, Britton JW, Huston J 3rd. Nonaneurysmal thunderclap headache with diffuse, multifocal, segmental, and reversible vasospasm. Cephalalgia. 1999;19(2):118–23.
6. Chen SP, Fuh JL, Lirng JF, Wang SJ. Is vasospasm requisite for posterior leuкоencephalopathy in patients with primary thunderclap headaches? Cephalalgia. 2006;26(5):530–6.
7. Calabrese LH, Gragg LA, Furlan AJ. Benign angiopathy: a distinct subset of angiographically defined primary angiitis of the central nervous system. J Rheumatol. 1993;20(12):2046–50.
8. Bogousslavsky J, Despland PA, Regli F, Dubuis PY. Postpartum cerebral angiopathy: reversible vasoconstriction assessed by transcranial Doppler ultrasonos. Eur Neurol. 1989;29(2):102–5.
9. Dodick DW, Eross EJ. A not so uncommon cause of thunderclap headache. Headache. 2002;42(6):555.
10. Jackson M, Lennox G, Jaspan T, Jefferson D. Migraine angiitis precipitated by sex headache and leading to watershed infarction. Cephalalgia. 1993;13(6):427–30.
11. Singhal AB, Caviness VS, Begleiter AF, Mark EJ, Rordorf G, Koroshetz WJ. Cerebral vasoconstriction and stroke after use of serotoninergic drugs. Neurology. 2002;58(1):130–3.
12. Kaye BR, Fainstat M. Cerebral vasculitis associated with cocaine abuse. JAMA. 1987;258(15):2104–6.
13. Chen SP, Fuh JL, Chang FC, Lin JC, Shia BC, Wang SJ. Transcranial color Doppler study for reversible cerebral vasospasm syndrome. Ann Neurol. 2008;63(6):731–7.

14. Chen SP, Fuh JL, Wang SJ, Chang FC, Ling JF, Fang YC, et al. Magnetic resonance angiography in reversible cerebral vasospasm syndrome. Ann Neurol. 2010;67(5):648–56.

15. Ducros A, Bokobza M, Porcher R, Sarov M, Valade D, Bousser MG. The clinical and radiological spectrum of reversible cerebral vasospasm syndrome. A prospective series of 67 patients. Brain. 2007;130(Pt 12):3091–101.

16. Ducros A, Fiedler U, Porcher R, Bokobza M, Staf P, Bous S. Hemorrhagic manifestations of reversible cerebral vasospasm syndrome: frequency, features, and risk factors. Stroke. 2010;41(11):2050–511.

17. Singhal AB, Haj-Ali RA, Topcuoglu MA, Fok J, Bena J, Yang D, et al. Reversible cerebral vasospasm syndromes: analysis of 139 cases. Arch Neurol. 2011;68(8):1005–12.

18. Caria F, Zedde M, Gamba M, Bersano A, Rasura M, Adami A, et al. The clinical spectrum of reversible cerebral vasospasm syndrome: the Italian project on stroke at young age (IPSYS). Cephalalgia. 2019;39(10):1:676–76.

19. Choi HA, Lee MJ, Choi H, Chung CS. Characteristics and demographics of reversible cerebral vasospasm syndrome: a large prospective series of Korean patients. Cephalalgia. 2018;38(4):765–75.

20. Lange KS, Forster O, Nawet J, Tuloup G, Burcin C, Cont L, et al. Type of headache at onset and risk for complications in reversible cerebral vasospasm syndrome. Eur J Neurol. 2022;29(1):130–7.

21. Patel SD, Topiwala K, Otite Oliver F, Saber H, Panza G, Mui G, et al. Outcomes among patients with reversible cerebral vasospasm syndrome: a nationwide United States analysis. Stroke. 2021;52(12):3970–7.

22. Singhal AB, Bernstein RA. Postpartum angiopathy and other cerebral vasospasm syndromes. Neurocrit Care. 2005;3(1):91–7.

23. Chen SP, Fuh JL, Wang SJ. Reversible cerebral vasospasm syndrome: current and future perspectives. Expert Rev Neurother. 2011;11(9):1265–76.

24. Singhal AB. Posterior reversible encephalopathy syndrome and reversible cerebral vasospasm syndrome as syndromes of cerebrovascular dysregulation. Continuum (Minneap Minn). 2021;27(5):1301–20.

25. Lin PT, Wang YF, Fuh JL, Lin JC, Ling JF, Ling YH, Chen SP, et al. Diagnosis and classification of headache associated with sexual activity using a composite algorithm: a cohort study. Cephalalgia. 2021;41(14):1447–57.

26. Shimoda M, Oda S, Hirayama A, Imai M, Komatsu F, Hoshikawa K, et al. Centripetal propagation of vasospasm at the time of headache resolution in patients with reversible cerebral vasospasm syndrome. Am J Neuroradiol. 2016;37(9):1594–9.

27. Shimoda M, Oda S, Shigematsu H, Hoshikawa K, Imai M, Komatsu F, et al. Clinical significance of centripetal propagation of vasospasm in patients with reversible cerebral vasospasm syndrome: a retrospective case–control study. Cephalalgia. 2018;38(12):1864–75.

28. Ducros A, Fiedler U, Porcher R, Bokobza M, Staf P, Bous S. Hemorrhagic manifestations of reversible cerebral vasospasm syndrome: frequency, features, and risk factors. Stroke. 2010;41(11):2050–511.

29. Topcuoglu MA, Singhal AB. Hemorrhagic reversible cerebral vasospasm syndrome: features and mechanisms. Stroke. 2016;47(7):1742–7.

30. Nawet J, Bokobza M, Franc J, Sarov M, Arnold M, Bousser MG, et al. Reversible cerebral vasospasm syndrome and cervical artery dissection in 20 patients. Neurology. 2013;81(9):821–4.

31. Garg A, Rocha M, Starr M, Ortega-Gutierrez S. Precursors and outcomes of hemorrhagic stroke in reversible cerebral vasospasm syndrome. J Neurol Sci. 2021;421:117312.

32. Haji-Ali RA, Furlan A, Abou-Chedeb A, Calabrese LH. Benign angiopathy of the central nervous system: cohort of 16 patients with clinical course and long-term followup. Arthritis Rheum. 2002;47(6):662–9.

33. Ray S, Kamath VW, Raju PA, Kn R. Fulminant reversible cerebral vasospasm syndrome in breakthrough COVID-19 infection. J Stroke Cerebrovasc Dis. 2022;31(2):106238.

34. Valencia-Mendoza M, Ramirez-Rodriguez N, Vargas-Avila N, Peña-Ortiz A, Corzo-Villianzam M, Serna-Ramirez L, et al. Fatal reversible cerebral vasospasm syndrome: a systematic review of case series and case reports. J Clin Neurosci. 2019;70:183–8.

35. Cho S, Lee MJ, Chung CS. Effect of nimodipine treatment on the clinical course of reversible cerebral vasospasm syndrome. Front Neurol. 2019;10:664.

36. Ling YH, Chen SP. Narrative review: headaches after reversible cerebral vasospasm syndrome. Curr Pain Headache Rep. 2020;24(12):74.

37. Chen SP, Fuh JL, Ling JF, Wang YF, Wang SJ. Recurrence of reversible cerebral vasospasm syndrome: a long-term follow-up study. Neurology. 2015;84(15):1552–8.

38. Boitet R, de Gaalon S, Duflot C, Marin G, Nawet J, Burcin C, et al. Long-term outcomes after reversible cerebral vasospasm syndrome. Stroke. 2020;51(2):670–3.

39. Buttner A. Review: The neuropathology of drug abuse: Neuropathol Appl Neurobiol. 2011;37(2):118–34.

40. Levine RJ, Maynard SE, Qian C, Lim KH, Englund LJ, Yu KS, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350(7):672–83.

41. Rana S, Karumanchi SA, Levine RJ, Venkatesha S, Rauh-Hain JA, Tamez H, et al. Sequential changes in angiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension. 2007;50(1):137–42.

42. Singhal AB, Kimberly WT, Schafer PW, Hedley-Whyte ET. Case records of the Massachusetts general hospital. Case 8-2009. A 36-year-old woman with headache, hypertension, and seizure 2 weeks post partum. N Engl J Med. 2009;360(11):1126–37.

43. Hamel E. Perivascular nerves and the regulation of cerebrovascular tone. J Appl Physiol (1985). 2006;100(3):1059–64.

44. Duckworth JW, Wellman GC, Walters CL, Bevan JA. Aminergic histochemistry and contractile responses to transmural electrical field stimulation and norepinephrine of human middle cerebral arteries obtained promptly after death. Circ Res. 1989;65(2):316–24.

45. Högsett ED, Andersson KE. On the postjunctional alpha-adrenoceptors in rat cerebral and mesenteric arteries. J Auton Pharmacol. 1984;4(3):161–73.

46. Mayhaw WG. Responses of cerebral arteries to activation of beta-adrenergic receptors during diabetes mellitus. Stroke. 1994;25(1):141–6.

47. Bartsynski WS. Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. AJNR Am J Neuroradiol. 2008;29(6):1043–9.

48. Bartsynski WS, Boardman JF. Catheter angiography, MR angiography, and MR perfusion in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol. 2008;29(3):447–55.

49. Topcuoglu MA, Chan ST, Silva GS, Smith EE, Kwong KK, Singhal AB. Cerebral vasomotor reactivity in reversible cerebral vasospasm syndrome. Cephalalgia. 2017;37(6):541–7.

50. Choi HA, Lee MJ, Chung CS. Cerebral endothelial dysfunction in reversible cerebral vasospasm syndrome: a case–control study. J Headache Pain. 2017;18(1):29.

51. Chen SP, Yang AC, Fuh JL, Wang SJ. Autonomic dysfunction in reversible cerebral vasospasm syndromes. J Headache Pain. 2013;14:94.

52. Chen SP, Chung YT, Liu TY, Wang YF, Fuh JL, Wang SJ. Oxidative stress and increased formation of vasoconsticting F2-isoprostanes in patients with reversible cerebral vasospasm syndrome. Free Radic Biol Med. 2013;61:243–8.

53. Hsu WH, Wang SJ, Chao YM, Chen CJ, Wang YF, Fuh JL, et al. Urine metabolomics signatures in reversible cerebral vasospasm syndrome. Cephalalgia. 2020;40(7):735–47.

54. Chen SP, Wang YF, Huang PH, Chi CW, Fuh JL, Wang SJ. Reduced circulating endothelial progenitor cells in reversible cerebral vasospasm syndrome. J Headache Pain. 2014;15:82.

55. Lee MJ, Cha J, Choi HA, Woo SY, Kim S, Wang SJ, et al. Blood-brain barrier breakdown in reversible cerebral vasospasm syndrome: implications for pathophysiology and diagnosis. Ann Neurol. 2017;81(3):454–66.

56. Cho S, Ling YH, Lee MJ, Chen SP, Fuh JL, Ling JF, et al. Temporal profile of blood-brain barrier breakdown in reversible cerebral vasospasm syndrome. Stroke. 2020;51(5):1451–7.
57. Chen SP, Chang YH, Chou CH, Juan CC, Lee HC, Chen LK, et al. Circulating microRNAs associated with reversible cerebral vasoconstriction syndrome. Ann Neurol. 2021;89(3):459–73.

58. Dodick DW. Thunderclap headache. J Neurol Neurosurg Psychiatry. 2007;21(6–11).

59. Armstrong FS, Hayes GJ. Segmental cerebral arterial constriction associated with pheochromocytoma: report of a case with arteriograms. J Neurosurg. 1961;18:843–6.

60. Im SH, Kim NH. Thunderclap headache after micturition in bladder pheochromocytoma. Headache. 2008;48(6):965–7.

61. Heo YE, Kwon HM, Nam HW. Thunderclap headache as an initial manifestation of pheochromocytoma. Cephalalgia. 2009;29(3):388–90.

62. Margolis MT, Newton TH. Methamphetamine (“speed”) arteritis. Neurosurg. 1961;18:843–6.

63. Tang-Wai DF, Phan TG, Wijdicks EF. Hypertensive encephalopathy in pregnancy. J Neurol Sci. 2016;370:83–8.

64. Shih YC, Chen SP, Fuh JL, Wang YF, Wang SJ. Influence of climate on 1-11β-hydroxysteroid dehydrogenase activity. J Autoimmun. 2009;33(2):87–91.

65. Roatta S, Micieli G, Bosone D, Losano G, Bini R, Cavallini A, et al. Neuroanatomical predictors of the oculomotor components in reversible cerebral vasoconstriction syndrome. Am J Ophthalmol. 2013;155(2):360–7.

66. Kasselman LJ, Sideris A, Bruno C, Perez WR, Cai N, Nicoletti JN, et al. Extracellular microRNAs activate nociceptor neurons to elicit pain via TRPV1 and TRPA1. Eur J Neurosci. 2014;40(2):257–65.

67. John S, Hajj-Ali RA, Min D, Calabrese LH, Cerejo R, Uchino K. Reversal of cerebral vasoconstriction syndrome with cardiac involvement during treatment for hyperthyroidism. J Clin Neurol. 2020;16(2):330–2.

68. Cracowski JL, Devillier P, Durand T, Stanke-Lubesque F, Bessard G. Vascular biology of the isoprostanes. J Vasc Res. 2003;13(8):93–103.

69. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Effect of generalised sympathetic activation by cold pressor test on cerebrovascular haemodynamics in healthy humans. J Auton Nerv Syst. 1998;71(2–3):159–66.

70. Brown CM, Sanya EO, Hitz MJ. Effect of cold face stimulation on cerebral blood flow in humans. Brain Res Bull. 2003;61(1):81–6.

71. Roatta S, Miceli G, Bosone D, Losano G, Bini R, Cavallini A, et al. Effect of generalised sympathetic activation by cold pressor test on cerebral haemodynamics in healthy humans. J Auton Nerv Syst. 1998;71(2–3):159–66.

72. Chen SP, Fuh JL, Wang YF, Tsai SJ, Hong CJ, Yang AC. Brain-derived neurotrophic factor gene Val66Met polymorphism modulates reversible cerebral vasoconstriction syndromes. PLoS ONE. 2011;6(3):e18024.

73. Kasselman LJ, Sideris A, Bruno C, Perez WR, Cai N, Nicoletti JN, et al. BDNF: a missing link between sympathetic dysfunction and inflammation? J Neuroimmunol. 2006;175(1–2):118–27.

74. Fletcher JJ, Kramer AH, Bleck TP, Solenski NJ. Overlapping features of eclampsia and postpartum cerebral angiopathy. J Neurol Sci. 2009;282(21):4067–9.

75. Park CK, Xu ZZ, Berta T, Han Q, Chen G, Liu XJ, et al. Extracellular microRNAs activate nociceptor neurons to elicit pain via TRPV1 and TRPA1. Eur J Neurosci. 2014;40(2):257–65.

76. Kasselman LJ, Sideris A, Bruno C, Perez WR, Cai N, Nicoletti JN, et al. Extracellular microRNAs activate nociceptor neurons to elicit pain via TRPV1 and TRPA1. Eur J Neurosci. 2014;40(2):257–65.

77. Fontaine D, Almairac F, Santucci S, Fernandez C, Dallel R, Pallud J, et al. Dural and pral pain-sensitive structures in humans: new inputs from awake cranialotomies. Brain. 2018;141(4):1040–8.

78. Park CK, Xu ZZ, Berta T, Han Q, Chen G, Liu XJ, et al. Extracellular microRNAs activate nociceptor neurons to elicit pain via TRPV1 and TRPA1. Eur J Neurosci. 2014;40(2):257–65.

79. He Y, Yang C, Kirkmire CM, Wang ZJ. Regulation of opioid tolerance by YAP/TAZ-miR-130/301 molecular circuit exerts systems-level control of fibrosis in a network of human diseases and physiologic conditions. Sci Rep. 2015;5:18277.

80. Fontaine D, Almairac F, Santucci S, Fernandez C, Dallel R, Pallud J, et al. Dural and pral pain-sensitive structures in humans: new inputs from awake cranialotomies. Brain. 2018;141(4):1040–8.

81. Krause DN, Duckles SP, Pelligrino DA. Influence of sex steroid hormones on cerebrovascular function. J Appl Physiol (1985). 2006;101(4):1252–61.

82. Laoeegopolkh, Sonti, Suwarna, Phan, and Runjan Ch. Reversal of cerebral vasoconstriction syndrome with cardiac involvement during treatment for hyperthyroidism. J Autoimmun. 2009;33(2):87–91.

83. Schulz E, Gori T, Munzel T. Oxidative stress and endothelial dysfunction in hypertension. Hypertens Res. 2013;36(6):665–73.

84. Conti V, Russomanno G, Corbi G, Izzo V, Vecchione C, Filippelli A, Adrenoreceptors and nitric oxide in the cardiovascular system. Front Physiol. 2013;4:321.

85. Yan QJ, Huang F, Hao F, Su XL, Meng Q, Xu MJ. Oxidative stress in the rostral ventrolateral medulla contributes to cardiovascular regulation in preeclampsia. Front Physiol. 2017;8:772.

86. Milne GL, Sanchez SC, Musiek ES, Morrow JD. Quantification of F2-isoprostanes as a biomarker of oxidative stress. Nat Protoc. 2007;2(1):221–6.
107. Hammad TA, Hajj-Ali RA. Primary angiitis of the central nervous system and reversible cerebral vasculitis syndrome. Curr Atheroscler Rep. 2013;15(8):346.

108. Rocha EA, Topcuoglu MA, Silva GS, Singhal AB. RCVS(2) score and diagnostic approach for reversible cerebral vasculitis syndrome. Neurology. 2019;92(7):e639–47.

109. Singhal AB, Topcuoglu MA, Fok JW, Kursun O, Nogueira RG, Frosch MP, et al. Reversible cerebral vasculitis syndrome and primary angiitis of the central nervous system: clinical, imaging, and angiographic comparison. Ann Neurol. 2016;79(6):882–94.

110. Serdaru M, Chiras J, Cujas M, Lhermitte F. Isolated benign cerebral vasculitis or migrainous vasospasm? J Neurol Neurosurg Psychiatry. 1984;47(1):73–6.

111. Han JS, Mandell DM, Poublianc J, Mardimae A, Slessarev M, Jaigobin C, et al. BOLD-MRI cerebrovascular reactivity findings in cocaine-induced cerebral vasculitis. Nat Clin Pract Neurol. 2008;4(11):628–32.

112. Chen CY, Chen SP, Fuh JL, Lirng JF, Chang FC, Wang YF, et al. Vascular wall imaging in reversible cerebral vasculitis syndrome—a 3-T contrast-enhanced MRI study. J Headache Pain. 2018;19(1):74.

113. Topcuoglu MA, Jha RM, George J, Frosch MP, Singhal AB. Hemorrhagic primary CNS angiitis and vasocostrictive drug exposure. Neurol Clin Pract. 2017;7(1):26–34.

114. Ashraf V, Bhasi R, Ramakrishnan KG, Praveenkumar R, Girija AS. Reversible cerebral vasculitis syndrome in a patient with systemic lupus erythematosus. Neurol India. 2012;60(6):635–7.

115. Chung SW, Lee KW, Heo SH, Ra R, Hong SJ, Yang HI, et al. A systemic lupus erythematosus patient with thunderclap headache: reversible cerebral vasculitis syndrome. Lupus. 2019;28(7):898–902.

116. Durrlemman C, Naggara O, Grevent D, Belot A, Desgranges M, Boyer O, et al. Reversible cerebral vasculitis syndrome in paediatric patients with systemic lupus erythematosus: implications for management. Dev Med Child Neurol. 2019;61(6):725–9.

117. Sadeghizadeh A, Pourmoghaddas Z, Zandifar A, Tara SZ, Rahimi H, Saleh R, et al. Reversible cerebral vasculitis syndrome and multisystem inflammatory syndrome in children with COVID-19. Pediatr Neurol. 2022;129:1–6.

118. Arandela K, Samudrala S, Abdalkader M, Anand P, Daneshmand A, Dassenbrock H, et al. Reversible cerebral vasculitis syndrome in patients with coronavirus disease: a multicenter case series. J Stroke Cerebrovasc Dis. 2021;30(12):106118.

119. Scheer M, Haider A, Wagner S, Ibe R, Prell J, Scheller C, et al. Case report of a fulminating non-aneurysmal convexity subarachnoid hemorrhage after COVID-19. Interdiscip Neurosurg. 2022;27:101437.

120. Finsterer J. First reported case of reversible cerebral vasculitis syndrome after a SARS-CoV-2 vaccine. Cureus. 2021;13(11):e19987.

121. Mansoor T, Alsarah AA, Mousavi H, Khader Eliyas J, Giotro T, Hussein O. COVID-19 associated reversible cerebral vasculitis syndrome successfully treated with nimodipine and aspirin. J Stroke Cerebrovasc Dis. 2021;30(7):105822.

122. Dakay K, Kaur G, Gulko E, Santarelli J, Bowers C, Mayer SA, et al. Reversible cerebral vasculitis syndrome and dissection in the setting of COVID-19 infection. J Stroke Cerebrovasc Dis. 2020;29(9):105011.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.